http://www.mbbp.com/ Boston-area business law firm en-us http://www.mbbp.com/resources/business/great-hill-massachusetts.html In an apparent case of first impression in Massachusetts, the Suffolk Superior Court ruled in Novack v. Raytheon Company, that when Company A acquires Company B, Company A owns and controls the attorney-client privilege applicable to communications between Company B and its counsel, even as to communications concerning the merger and the negotiations preceding it. In doing so, the Court applied the Delaware Chancery Court’s widely discussed decision in Great Hill Equity Partners IV, LP v. SIG Growth Equity Fund I, LLLP. But is Great Hill now the law in Massachusetts? http://www.mbbp.com/resources/iptech/mergers-privacy.html Merger and Acquisitions: Privacy and Compliance with Applicable Privacy Laws and Sharing of Customer Information http://www.mbbp.com/resources/iptech/robotics-patents.html As the robotics industry continues to advance and expand into areas including power source, actuation, sensors, mechanical manipulation, locomotion, interaction with surrounding environment, and human interaction, the patent portfolios that are built around these advancements will bring great value and sustainability to the innovators in this space. The patent attorneys that are lucky enough to work with these innovators are in for some exciting times. http://www.mbbp.com/news/firm/mbbp-utah.html The law firm of Morse, Barnes-Brown & Pendleton, PC is pleased to announce the opening of its office in Salt Lake City, Utah. Will serve fast-growing market in private equity and emerging growth companies. http://www.mbbp.com/resources/iptech/patent-attorney-how-to.html 10 Crucial Questions to Answer Before Contacting a Patent Attorney http://www.mbbp.com/resources/business/stockholder-acquiescence.html Despite contractual rights and protections, preferred stockholder silence or inaction may be interpreted as acquiescence to a breach, barring a plaintiff from both equitable and legal relief http://www.mbbp.com/resources/business/stock_option_pricing.html 10 Years of Valuations Under 409A by Attorneys Peter Barnes-Brown and Diana Española http://www.mbbp.com/resources/business/blocking-rights.html This case serves as an important reminder for practitioners on how damages may be imposed by a Delaware court if a party violates another party's contract right to consent to certain transactions and fundamentally calls into question the meaning of blocking rights, suggesting that if a contract remedy is appropriate, that may be the final remedy (in lieu of equitable relief). http://www.mbbp.com/news/firm/treannie-managing-partner.html The law firm of Morse, Barnes-Brown & Pendleton, PC is pleased to announce the election of Lisa Warren Treannie to the position of managing partner. http://www.mbbp.com/resources/business/social-media-diligence.html The buyer and seller in a merger and acquisition process often place a high value on the importance of maintaining a confidential process. A buyer is sensitive to the possibility that any leak could invite unwanted competition for the deal. A seller worries that widespread knowledge about an impending transaction and the uncertainty that knowledge creates might cause an unwanted business distraction. http://www.mbbp.com/resources/business/entity.html Founders of a new business typically realize early on that they need to conduct the business through a legal entity to limit their personal liabilities for the debts and obligations the business generates. Often, the three entity types from which the founders must choose are the C corporation, the S corporation and the limited liability company or LLC. http://www.mbbp.com/resources/iptech/biosimilar-patents.html Sandoz v. Amgen is the first instance in which a court has been asked to interpret the patent litigation provisions of the Biologics Price Competition and Innovation Act (the Biosimilars Act), and its outcome may have a significant impact on future biosimilar development by preventing biosimilar applicants from challenging patents in district court before completing clinical trials. Instead, Biosimilar applicants could turn to post grant proceedings created by the America Invents Act (AIA) to obtain patent certainty earlier in the biosimilar development process.